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Summary: Bullous pemphigoid is an autoimmune blistering disease. Most 
patients present autoantibodies against basement membrane proteins, 
specifically against type XVII collagen, which contains the immunodominant 
epitope NC16A. The pathogenesis of these antibodies has been demonstrated 
by in vitro and in vivo experiments. The divergence detected between NC16A 
and its murine homologue (NC14A) hinders the development of different animal 
models. In this article we demonstrate that patients’ sera affected of bullous 
pemphigoid induce dermal-epidermal separation over humanized murine skin 
produced by human epidermal stem cells from hair follicle.
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ABSTRACT  
 
Introduction. Bullous pemphigoid is an autoimmune disease. Patients have 
autoantibodies against proteins of the basement membrane zone. 
Autoantibodies against type XVII collagen are the most frequently detected, and 
their pathogenicity has been demonstrated by in vitro and in vivo experiments. 
Herein we present a novel animal model of bullous pemphigoid based on 
producing skin derived from human epidermal stem cells on mice.  
Patients and methods. Sera from seven patients with a diagnosis of bullous 
pemphigoid were collected. Humanized murine skin was obtained through co-
incubation of human epidermal stem cells and murine fibroblasts on the back of 
Swiss nude mice. Indirect immunofluorescence studies and dermal-epidermal 
separation with these sera were performed on human skin, humanized murine 
skin and native murine skin.  
Results. Serum IgG from 6/7 patients bound to the dermal-epidermal junction 
by IIF on both human and humanized murine skin. In 5/7, IgG deposition was 
observed on native murine skin, although with a lesser extent. All of the 7 sera 
were capable to induce dermal–epidermal separation on human and humanized 
murine skin. The presence of multiple hair follicles on native murine skin 
hindered the evaluation of this test; however, subepidermal separation was 
observed in 2/4 patients’ sera. 
Discussion. The non-collagenous 16A (NC16A) domain of type XVII collagen 
contains most of the immunodominant epitopes in human bullous pemphigoid. 
The murine homologue of NC16A, called NC14A, is completely different from its 
human counterpart, so, initial attempts to induce blisters in mice by the injection 
of human bullous pemphigoid antibodies failed. Our model circumvents this 
difficulty, since the resulting tissue expresses epithelial and basement 
membrane zone proteins of human origin.  
Conclusion. The present work presents a novel humanized animal model for 
bullous pemphigoid, of interest to further dissect the pathogenetic mechanisms 
of disease, and study the efficacy and side effects of potential therapies for 
bullous pemphigoid and other pathologically-related disorders.  
Martinez-Escala ME & Pascual G et al.   September 2011 
8 
 
INTRODUCTION 
 
Bullous pemphigoid (BP) is the most frequent autoimmune blistering disease, 
typical of the elderly and characterized by circulating and tissue-bound 
autoantibodies against the dermal-epidermal junction. Autoantibodies in BP 
patients are mainly directed to a couple of hemidesmosomal proteins: BP230 
(so-called BPAG1), an intracellular protein constituent of the hemidesmosomal 
plaque1, and the transmembrane protein BP180 (also termed BPAG2 or type 
XVII collagen)2.   
Patients with BP present with tense blisters on skin and occasionally on mucous 
membranes. A skin biopsy demonstrates a subepidermal blister with an 
eosinophil- and neutrophil-rich infiltrate in the superficial dermis. Deposition of 
C3 and/or IgG is detected by direct immunofluorescence (DIF) on healthy 
perilesional skin. Circulating antibodies against the basement membrane zone 
(BMZ) can be detected by indirect immunofluorescence (IIF) in 90% of the 
patients. Specific autoantibodies against BP230 can also be detected by 
immunoblot (IB) with epidermal or cultured keratinocytes’ extracts. 
Type XVII collagen (BP180) is a homotrimeric type II-orientation 
transmembrane protein, with a molecular weight of 180-kd. Its carboxy-terminal 
portion consists of 15 collagen domains of variable length that are separated 
from one another by short stretches of non-collagenous sequences (Figure 
1)3,4. Most BP sera recognize the membrane-proximal non-collagen linker 
domain (so-called non-collagenous 16A domain, NC16A)5, which is considered 
to contain the immunodominant epitopes, as in pemphigoid gestationis6. 
Besides, the pathogenic role of anti-NC16A autoantibodies has been 
demonstrated in several in vitro and in vivo experiments7,8.  
 
In vitro experiments 
Gammon et al9 originally developed an in vitro technique to study the potential 
of patients’ sera to induce subepidermal blisters on human skin cryosections. 
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Briefly, these sections were incubated with patients’ sera and leukocytes and a 
source of complement from healthy donors. The experiments were successful, 
however, at that moment the antigenic specificity of the pathogenic antibodies 
could not be demonstrated. Twenty years later, Sitaru et al8 demonstrated that 
IgG antibodies against the NC16A domain were responsible for blister formation 
by a similar in vitro approach. 
 
hBP180 NC16A      --- R S I L P Y G D S M D R I E --- 
mBP180 NC14A     --- -  -  V L Y H D V Q M D K S N --- 
Figure 1. At the top: schematic diagram showing the structural representation 
of the BP180 protein based on sequence analysis of the human cDNA10. At the 
bottom: comparison of the amino acid sequence alignment of the human and 
murine forms of BP180 in the region containing the major epitopes recognized 
by BP autoantibodies. Identical residues are marked in yellow, and conservative 
substitutions are highlighted in green7.  
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In vivo experiments 
Animal models of autoimmune disease are classified upon the origin of 
antibodies responsible for tissue damage (Table 1).  
 
Table 1. Classification of animals models of autoimmune blistering diseases. 
Spontaneous  Pathogenic autoantibodies spontaneously produced.  
BP has been described in horses and Yucatan minipigs. 
Passive transfer 
(Table 2) 
Antibodies are obtained from patients’ sera or from 
other animals previously immunized (e.g. rabbits, 
sheeps, chickens, etc.) and injected into different 
recipient animals (e.g. mice).  
Active disease 
(Table 3)  
The animal itself produces antibodies by transfer of 
autoreactive lymphocytes/splenocytes, or by protein 
immunization procedures (e.g. injection of a 
recombinant or synthetic form of the autoantigen with or 
without other adjuvants of the immune response) 
 
Specific BP animal models that have already been published are described in 
Tables 2 and 3. 
 
Passive transfer animal models 
The pathogenic relevance of antibodies in autoimmunity is directly 
demonstrated when antibodies from patients are injected into animals and they 
develop clinical lesions consistent with the human disease phenotype, together 
with compatible histological and DIF features. This technique did work in 
pemphigus vulgaris, pemphigus foliaceus and epidermolysis bullosa acquisita 
11-13, but was unsuccessful in BP14,15. Interestingly, BP patients’ IgG passively 
transferred into neonatal mice14 or monkeys15 exhibited little or no binding to the 
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cutaneous BMZ of the injected animals and produced no skin lesions. This 
phenomenon suggests that pathogenic human BP autoantibodies might not 
crossreact with its autoantigen counterpart in the experimental animal. It has 
already been shown that NC16A, the human BP180 immunodominant domain 
containing the major epitopes for BP, exhibits an unusually high degree of 
sequence divergence with its murine homologue (NC14A)7 (Figure 1), despite 
the high overall homology of human and murine BP180 (81.6%)7. For this 
reason, successful BP animal models are necessarily more elaborated, ranging 
from the use of human skin grafts to human NC16A transgenic models.  
Table 2. Passive transfer animal models of BP. 
Authors Antibodies origin Recipient animal Features 
Anhalt GJ et al  
(1981)16 
IgG isolated from BP 
patients 
Intracorneally into 
New Zealand white 
rabbits 
After 24h:  SE 
blisters.  
Positive DIF  
Liu et al  
(1993)7 
IgG  isolated from 
immunized rabbits 
Neonatal mice After 24h: SE 
blisters.  
Positive DIF 
Zillikens D et al  
(2001)17 
IgG isolated from 
patients and immunized 
rabbits 
SCID adult mice with 
human skin graft 
Blisters not induced. 
Negative DIF 
Yamamoto K et 
al 
 (2002)18 
IgG anti-hamster type 
XVII collagen from 
immunized rabbits 
Neonatal hamsters Microscopic 
subepidermal 
blisters.  
Positive DIF 
Nishie et al  
(2007)19 
Sera and IgG purified 
from BP patients 
Humanized NC16A 
knock-out mice 
After 48h: Erythema, 
blisters.  
Positive DIF  
Liu et al  
(2008)20 
IgG  isolated from BP 
patients sera 
Humanized NC16A 
knock-out mice 
SE blisters, with 
inflammatory 
infiltrate.  
Positive DIF  
Nishie et al  
(2009)21 
Transplacental transfer 
of mother antibodies 
Neonatal humanized 
NC16A knock-out 
mice 
SE blisters.  
Positive DIF 
SE: subepidermal, DIF: direct immunofluorescence, SCID: severe combined 
immunodeficiency. 
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Active animal models 
Active animal models are well suited to investigate the pathogenetic 
mechanisms of autoimmune diseases (initial loss of immune tolerance, factors 
that influence the perpetuation of the autoantibody response, effector 
mechanisms of tissue injury) and to study the efficacy and safety of long-term 
therapeutic interventions. Nevertheless, despite these models duplicate the 
clinical phenotype, the histological, ultrastructural and immunological aspects of 
human disease, we should be aware that these are fully murine systems since 
autoantibody production occurs within the same organism22. In short, the role of 
human autoantibodies cannot be investigated.  
 
Table 3. Active animal models of BP. 
 Authors 
 
Immunization 
technique 
Receipt 
animal 
Features 
Transgenic 
models 
Olasz et al 
 
(2007)
23
 
Autoantibodies Wild type mice 
with skin grafts 
from human 
Col17
+/+
 
transgenic mice 
Histological 
changes of BP. 
Positive DIF 
Transfer of 
autoreactive 
lymphocytes 
Ujiie et al 
(2010)
24
 
Spleen lymphocytes 
from Wild-type 
C57BL/6 with 
transplanted skin from 
mCol17 deficient mice 
Rag2
-/- 
mice Skin lesions 
resembling BP 
Forced 
immunization 
models 
Hall RP et al 
(1993)
25
 
Injection of a protein 
encoding a BP230 
epitope, plus 
ultraviolet-B irradiation 
Rabbits Inflammatory 
reaction on the 
irradiated skin. 
Deposition of 
IgG and C3 
 
In this work, we describe a new animal model consisting of growing skin from 
epidermal human stem cells on Swiss nude mice. Herein we present the results 
of in vitro experiments that validate its potential use as a model for BP and other 
autoantibody-induced related skin diseases. We demonstrate the in vitro ability 
of human BP sera to bind to the DEJ and induce dermal-epidermal separation.  
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PATIENTS AND METHODS 
 
Patients’ sera. Serum samples from 2 healthy donors and 7 BP patients prior to 
the initiation of therapy were collected. All BP patients were characterized by: a) 
skin blisters, b) subepidermal blisters on the skin biopsy, c) deposition of C3 +/- 
IgG at the DEJ by DIF study of healthy perilesional skin. An enzyme-linked 
immunoabsorbent assay (ELISA) was performed for each sample to determine 
anti-BP180 antibody levels (Table 4). 
 
Table 4. BP180 ELISA results from 7 BP patients (positive if >9 U/ml). 
 
 
 
 
 
 
 
 
 
 
Preparation of skin cryosections. Human stem-cell-derived skin grown on Swiss 
nude mice, native skin from C57BL/6 mice, and neonatal human foreskin 
obtained from routine circumcision, were washed in cold phosphate-buffered 
saline (PBS), cut in pieces of 5 x 15 mm, embedded in optimum cutting 
temperature (OCT) compound and stored at -80ºC. Four cryosections of 6 μm 
were placed in the centre of each Superfrost Plus microscope slide (Menzel-
Patients Age Gender BP180 ELISA 
BP1 83 M 159.03 
BP2 77 F 13.00 
BP3 82 F 27.90 
BP4 80 M 2.00 
BP5 87 F 45.90 
BP6 86 M 124.90 
BP7 82 M 9.00 
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Gläser, Braunschweig, Germany)9. IIF studies were also performed on 1 M 
NaCl-split human skin following a previous protocol26. 
Humanized skin on Swiss nude mice. Humanized skin was developed on the 
back of Swiss nude mice (athymic mice) by in situ coincubation of epidermal 
cells from the bulge of human hair follicles and cutaneous or mucous fibroblasts 
from C57BL/6 mice. Briefly, a mixture of both cell types was transplanted and 
incubated for one week within a silicon chamber sticked over the mice back 
after performing an incisional wound. After 8 to 10 weeks, skin biopsies were 
obtained and processed as explained above. Humanized skin produced with 
mucous fibroblasts was used, since it lacked hair follicles.   
Indirect immunofluorescence microscopy studies (Figure 2).  Sera dilutions 1:10 
in PBS with 1% bovine serum albumin were incubated for 60 minutes in a 
humidified dark chamber at 37ºC. After three washes of 7 minutes with PBS, 
slides were incubated with a FITC-labelled goat anti-human IgG (Sigma-Aldrich, 
St Louis, MO) for 30 minutes at 37ºC. After extensive washing with PBS, slides 
were topped with glass covers (Menzel-Gläser, Braunschweig, Germany) after 
the addition of fluorescent mounting medium (DAKO Cytomation, Glostrup, 
Denmark). Slides were observed with a fluorescence microscope (Olympus 
BX51, Olympus, San Diego, CA). 
IIF results were evaluated as follows (subjective quantification): 
- An intermittent or continuous linear IgG deposition was not detected along the DEJ 
+ Intermittently positive linear IgG deposition along the DEJ  
++ Slight continuous IgG deposition along the DEJ 
+++ Moderate continuous IgG deposition along the DEJ  
++++ Strong continuous IgG deposition along the DEJ 
    (Subjective quantification by two observers)  
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Figure 2. Indirect immunofluorescence protocol (Ab: antibody, FITC: 
Fluorescein isothiocyanate) 
Peripheral blood leukocytes. Peripheral blood leukocytes from healthy donors 
were isolated by sedimentation gradient containing a 3% 500 mM dextran 
solution (Nycomed, Oslo, Norway). Cells were harvested, washed twice in 
RPMI 1640 (Life Technologies, Karlsruhe, Germany) and resuspended in the 
same medium. Approximately, a concentration of 1x107 cells/ml in the culture 
medium is needed to perform the dermal-epidermal separation assay. The cell 
suspension was kept on ice and cell viability was tested using trypan blue 
staining; only preparations with viability higher than 95% were used.  
Induction of dermal-epidermal splits by BP patients’ sera and leukocytes on 
cryosections of human skin, humanized murine skin and native murine skin 
(Figure 3)8,9. Briefly, cryosections were rehydrated with PBS for 10 minutes to 
remove the embedding medium. Slides were incubated with patients’ and 
control sera diluted 1:1 in NeutrAB (Medion Diagnostics, Miami, FL) in a 
humidified chamber at 37ºC for 120 – 180 minutes. After washing the sections 
with PBS twice, slides were covered with a second slide leaving a 0.03 mm 
space in between. Approximately 500 µl of the cell suspension were introduced 
and incubated for 90 to 180 minutes at 37ºC in a humidified air incubator 
containing 5% CO2. Chambers were finally disassembled, sections were 
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washed in PBS for 10 minutes, air-dried for 10 minutes, fixed in formalin and 
stained with hematoxylin and eosin.  
Figure 3. Induction of dermal-epidermal separation on human skin, humanized 
murine skin and native murine skin sections.  
Sections were evaluated on a light microscope as follows: 
- No split is observed 
I 0 – 25% of dermal-epidermal separation 
II 25 – 50% of dermal-epidermal separation 
III 50 – 75% of dermal-epidermal separation 
IV 75 – 100% of dermal-epidermal separation 
Percentages expressed above consider the length of dermal-epidermal 
separation with regard to the total DEJ length. 
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Figure 4. Hematoxylin and eosin staining, 400x. A close-up view of a focus of 
dermal-epidermal separation (arrow).   
Martinez-Escala ME & Pascual G et al.   September 2011 
18 
 
RESULTS 
 
Results are summarized in Table 5. 
 
Serum antibodies from BP patients bind to both humanized and native murine 
skin  
IIF study of 6/7 BP sera on human salt-split skin showed a strong fluorescence 
on the roof of the blister. Results were similar for the same six patients on 
humanized murine skin. One of the patients’ sera (BP2) demonstrated a 
combined staining of both the roof and the floor of the split. Five of seven 
patients’ sera were also positive on native murine skin, though to a lesser extent 
compared with human skin and humanized murine skin. These results failed to 
correlate with the BP180 ELISA levels.  
 
 
Figure 5. IIF of BP1 serum on the 3 different skin substrates.  
a) 200x. A moderate deposit of IgG on the roof of the blister is observed on SSS 
of human foreskin. b) 400x. Moderate continuous deposit of IgG in the BMZ on 
humanized murine skin. c) 200x. Intermittent deposition of IgG in the BMZ on 
native murine skin 
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Figure 6. IIF of BP2 serum on the 3 different skin substrates.  
a)200x. Moderate continuous deposit of IgG in a mix pattern (roof an floor) is 
observed SSS human foreskin. b)400x. Slight continuous deposit of IgG in BMZ 
on native murine skin. c)200x. Intermittent deposition of IgG in BMZ on native 
murine skin 
 
Sera from BP patients induce subepidermal splits in cryosections of humanized 
and non-humanized murine skin 
All BP patients’ sera incubated with leukocytes induced dermal-epidermal 
detachment in humanized murine skin, to a similar extent to that found on 
human skin. The presence of hair follicles in native murine skin hindered a 
correct assessment of the dermal-epidermal separation, although we were able 
to observe detachment in 2 out of 4 sections that were adequate for evaluation. 
The degree of dermal-epidermal separation did not significantly correlate with 
the levels of anti-BP180 IgG as detected by ELISA.  
 
Martinez-Escala ME & Pascual G et al.   September 2011 
20 
 
c 
Figure 7.  
a) HE 100x. A whole-length dermal-epidermal separation is induced by BP6 
serum on humanized skin. b) HE 200x. A close-up view of blister formation by 
BP7 serum. c) HE 200x. Dermal-epidermal separation induced by BP6 serum 
on native murine skin. 
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Table 5. Summary of IIF and dermal-epidermal separation study results.  
HS: human skin, HMS: humanized murine skin, NMS: native 
murine skin, NA: not available 
 
 
Patients BP180 ELISA 
values (U/ml) 
Skin 
substrate 
IIF Subepidermal 
separation 
BP1 159.03 HS +++ IV 
HMS ++ IV 
NMS - - 
BP2 13.00 HS ++  
(Mixed pattern) 
IV 
HMS ++ III 
NMS + NA 
BP3 27.90 HS - IV 
HMS - III 
NMS - NA 
BP4 2.00 HS +++ IV 
HMS ++ II 
NMS ++ NA 
BP5 45.90 HS ++ II 
HMS ++ II 
NMS - - 
BP6 124.90 HS ++++ IV 
HMS +++ III 
NMS ++ II 
BP7 9.00 HS +++ III 
HMS ++ III 
NMS + I 
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DISCUSSION 
 
We demonstrate by IIF study that IgG binds to the BMZ of humanized skin, 
similar to what happens in human skin. Interestingly, IgG linear deposition is 
also observed when using native murine skin, although to a much lesser 
degree. This IgG staining of the BMZ on native murine skin might be explained 
by two mechanisms: 1) BP IgG contains anti-BMZ antibodies other than those 
against type XVII collagen (e.g. anti-BP230), and 2) there might be some 
degree of cross-reactivity between certain human antibodies and murine BMZ 
proteins, based on inter-species protein homology. In other words, BP sera are 
immunologically characterized by non-restricted autoantibody response, since 
they contain several antibodies against other epitopes different from NC16A, as 
well as antibodies against other BMZ molecules different from type XVII 
collagen, which are also present in native murine skin. Nonetheless, the role of 
these latter autoantibodies in the pathogenesis of BP has not yet been 
demonstrated27. 
Specifically regarding the antigen-antibody reactivity of anti-type XVII collagen 
antibodies among species, available studies are controversial. For instance, in 
the study by Liu et al28, rabbit anti-human (hBP180) antibodies reacted with a 
recombinant form of human BP180 (mBP180) or mouse skin, by IB and IF 
studies, respectively. Conversely, rabbit anti-mBP180 antibodies reacted with 
recombinant mBP180 and mouse skin, but did not bind to hBP180 or human 
skin. In contrast, a recent study has found reactivity of human anti-NC16A 
antibodies with both the human NC16A domain and its murine homologue, 
NC14A (Sesarman et al., unpublished data). Our results are in line with last 
findings. Further studies are needed to clarify this aspect. 
With regard to the question whether is an association between the intensity of 
the BMZ staining (by IIF) and type XVII collagen ELISA levels, we failed to 
detect a significant correlation. This might also be explained by the presence in 
BP sera of antibodies against epitopes and proteins other than NC16A and type 
XVII collagen, respectively27.  
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In our last set of experiments, dermal-epidermal separation was similarly 
induced by BP sera on both humanized murine skin and human skin. 
Importantly, a certain degree of dermal-epidermal detachment was observed in 
two out of four cryosections of native murine skin (other slides could not be 
evaluated due to the presence of hair follicles that hindered the artificial split 
induction). 
Mechanisms of antibody-induced blister formation in BP are dependent upon 
the activation of complement, degranulation of dermal mast cells and 
generation of neutrophil-rich infiltrates, which release proteinases and reactive 
oxygen species (ROS)7,29,30,31. Experiments transferring pathogenic BP 
antibodies into mice failed to induce a blistering phenotype when performed in 
mice deficient in complement, Fcγ-receptors (receptors of the constant portion 
of γ-immunoglobulins)32, neonatal mice with immature innate immune system, a 
BP-like eruption is not observed (Table 6).  It is already known that T and B 
lymphocytes are implicated in loss of tolerance and the initiation of autoimmune 
response. Nevertheless, T and B lymphocytes are not required for effector 
mechanisms leading to blister formation, which is demonstrated by experiments 
showing that the injection of BP IgG induces blistering in mice deficient in T 
cells (T-cell deficient nude mice) and mice deficient in both T and B cells 
(C57BL/6J Rag1 tm1Mom)33. 
Table 6. Main requirements for blister induction. 
Requirements antibody-blisters formation 
1. Crossreactivity between antibody-antigen 
 Human antibody against transgenic human NC16A mouse 
 Rabbit IgG against murine NC14A (homologue of human NC16A) 
2. Innate immune system preserved 
 Complement activation 
 Fcγ-receptors  
 Neutrophils 
 Mast cells 
 Release of proteinases 
 Release of oxygen metabolites 
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Different animal models of BP are available, each one with its own specificities. 
These specific features make one model adequate or not to study certain 
aspects of disease immunopathology (Table 7). For instance, passive transfer 
models are appropriate to dissect the pathogenetic mechanisms of the effector 
systems leading to tissue damage. In contrast, active immunization models are 
best preferred to study the phenomena responsible for the loss of immune 
tolerance to autoantigens, as well as for therapeutic assays addressed to 
modulate the chronic autoimmune response22. 
 
Table 7. Research purpose for each animal model. 
Passive transfer in 
neonatal and adult 
mice 
Tissue damage induced by antibodies (insights of 
inflammatory events) 
Passive transfer into 
mice transplanted 
with human skin or 
humanized skin 
Tissue damage induced by antibodies (insights of 
inflammatory events) 
Characterization of clinical, histological and 
immunological features of human BP 
Autorreactive 
lymphocytes 
transfer, active 
model 
Study cells of immune system that are mediating 
autoimmune response, development of cell-based 
therapy 
Transgenic models, 
active models 
Allows to study all aspects of autoimmune blistering 
disease and long-term effect of therapeutic 
interventions 
 
The use of human skin grafts on mice represents an attempt to make animal 
models of inflammatory skin diseases closer to what really happens in human 
diseased skin.  
 
To our knowledge, only one study using this approach has already been 
described for BP, unfortunately, with negative results. This study, performed by 
Zillikens and colleagues17, consisted of engrafting human skin from healthy 
donors onto SCID immunodeficient mice. Interestingly, anti-BP180 IgG 
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autoantibodies from BP patients’ sera and from a rabbit immunized with a 
recombinant form of human BP180, strongly bound to the DEJ of the graft, 
weakly fixed murine complement and induced a mild neutrophil-rich infiltrate on 
the upper dermis, but failed to induce clinically evident subepidermal blisters or 
dermal-epidermal separation on histopathological study. Thus, this model 
cannot really be considered a model of BP. 
 
Two other experimental studies using skin grafts of humanized murine skin 
have been reported.  
 
The first model using grafts of murine skin expressing human type XVII 
collagen, was described by Olasz et al23. Transgenic skin grafts onto wild-type 
mice induced an IgG response that labeled the basement membrane zone of 
human skin and transgenic humanized murine skin, but not skin from wild-type 
mice, by indirect IF study. This IgG was deposited at the DEJ of the recipient 
mice, which subsequently developed C3 deposition at the same level, recruited 
neutrophils to the dermal-epidermal junction and the papillary dermis, and 
finally, frank subepidermal blister formation. In this model, in contrast to ours: 
(a) human skin or human-derived skin is not used, and (b), this is an active 
experimental model.  
 
The second model, by Ujiie and colleagues24, consisted of engrafting murine 
skin expressing human type XVII collagen (from transgenic COL17m-/-,h+ mice) 
on wild-type mice to induce an autoimmune response against human type XVII 
collagen. Splenocytes from the immunized wild-type mice were injected into 
Rag-2-/- / COL17m-/-,h+ mice (expressing human type XVII collagen), which led to 
a continuous production of anti-human type XVII collagen IgG antibodies and a 
blistering phenotype clinically and immunopathologically typical of BP (except 
for the lack of an eosinophil infiltrate). Therefore, this model represents an 
active model of BP, in which: (1) no human skin graft is used, but a murine skin 
graft from COL17-humanized mice, and (2) this murine graft is not used in the 
recipient mice showing the blistering phenotype, but as the method to immunize 
wild-type animals with the human-sequence autoantigen, to serve them as 
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simple providers of reactive splenocytes to be transferred into COL17-
humanized knock-out mice. These are indeed some of the differences with our 
model.  
Interestingly, in both the last models23,24, CD4+ cells were necessary for the 
development of the blistering phenotype, in contrast to CD8+ cells, which were 
not relevant.  
After comparing with the above-mentioned studies, we can conclude that our 
model, although in a preliminary stage, is unique novel model since it is the only 
passive transfer model in which the recipient animals carry a skin graft obtained 
from human epidermal stem cells (Table 8 summarizes the main features of the 
animal model presented). In this regard, our grafts can be considered a 
chimeric skin formed by the interaction and differentiation of human stem cells 
and murine fibroblasts.  
Our grafts potentially express a variety of human epidermal proteins, as it was 
demonstrated with involucrin, a specific human protein that differentiate human 
from murine keratinocytes. We have not directly demonstrated that all BMZ 
proteins are of human origin, however, we assume this fact based on previous 
studies34-36, which shows, first, that keratinocytes produce almost all proteins 
present in the BMZ (including type XVII collagen), and second, that fibroblasts 
just modulate this synthesis.  It is worthwhile to remark this last feature, in 
contrast to other models using COL17-humanized transgenic mice, in which the 
only human protein expressed is type XVII collagen. Based on this fact, this 
model would allow us to study the pathogenetic role of other autoantibodies 
which bind to other autoantigens other than type XVII collagen. This possibility 
would be of great interest, since BP and other related diseases are commonly 
associated to a heterogeneous response to more than one autoantigen, such 
as BP230, integrins, etc.  
Finally, the next experiments that we must perform to better characterize our 
model are: (1) in vitro assay of the induction of subepidermal separation on 
cryosections of chimeric skin grafts with affinity-purified anti-NC16A IgG, and (2) 
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in vivo injection of total IgG and affinity-purified anti-NC16A IgG antibodies from 
BP patients’ sera.  
One limitation of our experimental work presented here is that these data only 
form in vitro experiments, where human leukocytes are used to induce dermal-
epidermal separation, in contrast to the in vivo situation where components of 
the innate immunity (granulocytes, complement and coagulation system) are 
provided by mice. 
 
Table 8. Summary of features of our probably new animal model. 
Passive transfer animal model 
Adult mice 
Athymic nude mice 
Innate immune system preserved 
Humanized grafted skin (epidermal and BMZ human proteins) 
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CONCLUSIONS 
The pathogenic relevance of antibodies in autoimmune diseases is 
demonstrated when patients’ antibodies are injected into animals and they 
develop signs of tissue injury that are clinically and immunopathologically 
suggestive of the human disease.  
With regard to experimental BP, initial attempts to induce a blistering phenotype 
by the passive transfer of patients’ IgG were unsuccessful, fact that is partially 
explained by the lack of cross-reactivity of human autoantibodies with the 
murine antigen counterpart. For this reason, experimental BP models are more 
elaborated and use different approaches, ranging from human full skin grafts to 
human NC16A transgenic mice.  
In contrast to previous studies, in our model epidermal proteins are originated 
from human stem cells –thus, human proteins are expressed- while obviating 
the need of genetic manipulation. Future passive transfer experiments must be 
performed to consider the present model as a valid experimental BP model.  
Finally, we hope that this study may help dissecting the effector mechanisms of 
tissue damage in BP and identifying potential therapeutic targets.   
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